This information is intended only for healthcare professionals resident in the Great Britain

Prescribing Information (PI) for Bosulif® (bosutinib) Great Britain (GB) and Northern Ireland (NI)​​​​​​​​​​

Pfizer Ltd. accepts no responsibility for the content or services of the linked site other than the information relating to Pfizer medicines which it has provided or reviewed

Great Britain

  • Bosulif (bosutinib) 100mg tablets - PI for GB
  • Bosulif (bosutinib) 400mg tablets - PI for GB
  • Bosulif (bosutinib) 500mg tablets - PI for GB

Northern Ireland

  • Bosulif (bosutinib) 100mg, 400mg and 500mg tablets - PI for NI

Bosulif (bosutinib) 100mg tablets - PI for GB

Bosulif (bosutinib) 400mg tablets - PI for GB

Bosulif (bosutinib) 500mg tablets - PI for GB

Bosulif (bosutinib) 100mg, 400mg and 500mg tablets - PI for NI

PP-BOS-GBR-1606. June 2022